EAP Achieves WHO Accreditation as a Non-State Actor

September 30, 2025

The European Academy of Paediatrics (EAP) is delighted to confirm that it has been officially accredited as a non-State actor to the WHO Regional Committee for Europe. The decision was published by WHO on 16 September 2025 (Provisional Agenda Item 7) in the working document EUR/RC75/21: Engagement with non-State actors: accreditation and triennial review

This accreditation will be formally noted during the upcoming 75th session of the WHO Regional Committee for Europe (Copenhagen, 28-30 October 2025). Once recognized in that forum, EAP will gain the right to attend and contribute to meetings of the Regional Committee, enhancing our role in shaping regional child-health policy.

This milestone reflects many months of sustained effort and coordination by EAP leadership, with special thanks to the President, Prof Berthold Koletzko. It represents a significant step forward in our goal of ensuring paediatric expertise is heard and valued across Europe.

WHO Document Link: “Engagement with non-State actors: accreditation and triennial review” (EUR/RC75/21, published 16 September 2025). Download the PDF from the EAP website below or read on the WHO’s website.

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative: